T1 mapping and survival in systemic light-chain amyloidosis.
Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, Piechnik SK, Whelan CJ, Herrey AS, Gillmore JD, Lachmann HJ, Wechalekar AD, Hawkins PN, Moon JC. · 2015
Read T1 mapping and survival in systemic light-chain amyloidosis. by Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, Piechnik SK, Whelan CJ, Herrey AS, Gillmore JD, Lachmann HJ, Wechalekar AD, Hawkins PN, Moon JC. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4301598.txt.
Introduction
Sanjay M Banypersad and eleven co-authors tested whether heart MRI measures predict survival in systemic light chain amyloidosis. Their study appeared in the European Heart Journal in 2015. In this disease, faulty antibody proteins deposit in organs, and heart involvement is the main driver of early death.
One hundred patients had MRI scans that map a signal called T1 and estimate how much of the heart wall is taken up by deposits. Both measures ran high in patients and tracked with blood markers and heart function. During follow up, in which a quarter of the patients died, the deposit measure separated those at highest risk. The scan values add a noninvasive way to grade danger in this disease.
Catalog record
| CREATOR | Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, Piechnik SK, Whelan CJ, Herrey AS, Gillmore JD, Lachmann HJ, Wechalekar AD, Hawkins PN, Moon JC. |
|---|---|
| YEAR | 2015 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
T1 mapping and survival in systemic light-chain amyloidosis By Sanjay M Banypersad, Marianna Fontana, Viviana Maestrini, Daniel M Sado, Gabriella Captur, Aviva Petrie, Stefan K Piechnik, Carol J Whelan, Anna S Herrey, Julian D Gillmore, Helen J Lachmann, Ashutosh D Wechalekar Published in: European Heart Journal DOI: 10.1093/eurheartj/ehu444 ABSTRACT Abstract Aims To assess the prognostic value of myocardial pre-contrast T1 and extracellular volume (ECV) in systemic amyloid light-chain (AL) amyloidosis using cardiovascular magnetic resonance (CMR) T1 mapping. Methods and results One hundred patients underwent CMR and T1 mapping pre- and post-contrast. Myocardial ECV was calculated at contrast equilibrium (ECVi) and 15 min post-bolus (ECVb). Fifty-four healthy volunteers served as controls. Patients were followed up for a median duration of 23 months and survival analyses were performed. Mean ECVi was raised in amyloid (0.44 ± 0.12) as was ECVb (mean 0.44 ± 0.12) compared with healthy volunteers (0.25 ± 0.02), P < 0.001. Native pre-contrast T1 was raised in amyloid (mean 1080 ± 87 ms vs. 954 ± 34 ms, P < 0.001). All three correlated with pre-test probability of cardiac involvement, cardiac biomarkers, and systolic and diastolic dysfunction. During follow-up, 25 deaths occurred. An ECVi of >0.45 carried a hazard ratio (HR) for death of 3.84 [95% confidence interval (CI): 1.53–9.61], P = 0.004 and pre-contrast T1 of >1044 ms = HR 5.39 (95% CI: 1.24–23.4), P = 0.02. Extracellular volume after primed infusion and ECVb performed similarly. Isolated post-contrast T1 was non-predictive. In Cox regression models, ECVi was independently predictive of mortality (HR = 4.41, 95% CI: 1.35–14.4) after adjusting for E:E′, ejection fraction, diastolic dysfunction grade, and NT-proBNP. Conclusion Myocardial ECV (bolus or infusion technique) and pre-contrast T1 are biomarkers for cardiac AL amyloid and they predict mortality in systemic amyloidosis. Keywords: ECV, Amyloid, CMR, Cardiomyopathy, Heart failure, T1 mapping See page 203 for the editorial comment on this article (doi:10.1093/eurheartj/ehu442) INTRODUCTION Systemic amyloid light-chain (AL) amyloidosis is a multiorgan, infiltrative disorder caused by an underlying plasma cell dyscrasia and is characterized by tissue and organ amyloid deposition with interstitial expansion. Cardiac involvement is present in ∼50% of patients at presentation and is the principal driver of prognosis. Treatment comprises chemotherapy or autologous stem cell transplantation to suppress clonal light-chain production, which may retard disease progression or facilitate regression.1 Current predictors of survival rely on measuring surrogate rather than direct markers of interstitial expansion. Concentration of the serum biomarkers NT-proBNP and Troponin T form the basis of the Mayo Staging classification2 but are influenced by renal impairment which is present in a quarter of patients at presentation. ECG criteria, low limb lead voltages,3 or fragmented QRS complexes4 are also predictive, but are confounded by pericardial effusions and conduction abnormalities. Echocardiographic parameters also predict outcome,5–7 but coexisting causes of left ventricular hypertrophy or diastolic impairment may affect interpretation. Cardiovascular magnetic resonance (CMR) using the late-gadolinium enhancement (LGE) technique adds value in the diagnosis of cardiac involvement in AL amyloidosis. Altered gadolinium kinetics also shows some correlation with survival.8 Recently we have shown that pre-contrast, native myocardial T1 mapping correlates with cardiac disease burden and detects early disease.9 T1 mapping pre- and post-contrast can be used to derive the partition coefficient and, with the haematocrit, the myocardial extracellular volume (ECV)10–12 which is a direct measurement of myocardial interstitium and therefore likely a surrogate marker of amyloid burden.13,14 The ECV can also assess amyloid burden in other organs.15 Furthermore, in other cardiac diseases, myocardial ECV predicts outcome.16 Technically, measurement of the ECV requires equilibration of contrast concentrations between blood and myocardium, which can be achieved precisely using a somewhat cumbersome primed contrast infusion,10 or sufficiently through delayed study following administration of a bolus of gadolinium. Both techniques measure ECV the same where the ECVs are typically 0.4 or less, but one paper has shown a bias towards over-estimation of the true ECV in high ECV conditions (including n = 20 amyloid patients).17 We hypothesized firstly that the myocardial ECV and pre-contrast T1 would correlate with disease burden in cardiac AL amyloidosis as assessed by current measures. Additionally, we tested the ability of both biomarkers as predictors of survival in AL amyloidosis by comparing the predictive power of: ECV after primed infusion (ECVi); pre-contrast T1; bolus-only ECV (ECVb); and post-contrast T1. METHODS The research was approved by The UCL/UCLH Joint Committees on the Ethics of Human Research Committee and all participants provided informed, written consent prior to enrolment. One hundred consecutive patients with systemic AL amyloidosis who were assessed between 2010 and 2012 at the National Amyloidosis Centre (Royal Free Hospital, London, UK) and in whom there were no contraindications to CMR (presence of non-MR compatible devices) or contrast administration (GFR < 30 mLs/min) or potential confounders to T1 measurement (known atrial fibrillation at first visit) were recruited. These 100 patients include all 60 patients studied previously in the baseline study.13 Approximately 25% of patients with systemic AL amyloidosis seen at the centre during this period had an eGFR of <30 mL/min/1.73 m2 and were therefore excluded. Six patients who were found to have atrial fibrillation/flutter once in the scanner after they had consented were not excluded. All patients had histological proof of systemic AL amyloidosis except 2 (2%), who died before biopsy could be undertaken, but in whom monoclonal gammopathies were present and the organ distribution of amyloid on SAP scintigraphy was characteristic of AL type. Histology was performed with Congo red followed by immunohistochemical staining; tissues examined were: kidney (26%), endomyocardium (7%), bone marrow (13%), upper gastrointestinal tract (7%), liver (3%), fat (15%), spleen (1%), lung (1%), rectum (9%), soft tissues (12%, included skin, tongue, buccal mucosa, labia), lymph node (3%), and peritoneum (1%). All patients underwent 12 lead ECG, assays of the cardiac biomarkers NT-proBNP and Troponin T, and echocardiography at baseline. Mean ECG QRS voltage in limb and praecordial leads were calculated.18 Echocardiographic assessment of diastolic function was performed using the E:E′ ratio. Where transmitral E-wave deceleration time and isovolumetric relaxation time were available, a diastolic dysfunction grade of 0–3 was assigned according to established British Society of Echocardiography (BSE) criteria. All additionally underwent conventional CMR on a 1.5 T magnet (Avanto, Siemens). T1 mapping was performed using the Shortened Modified Look Lockers Inversion (ShMOLLI) recovery sequence19 pre- and post-contrast (0.1 mmol/kg bolus and 0.0011 mmol/kg/min infusion of Dotarem™) as part of the Equilibrium CMR (EQ-CMR) technique, the post-contrast T1 map being performed at 15 min and after equilibration (mean time from bolus 45 min), as previously described.10 Analysis Standard CMR parameters of structure (left ventricle (LV) mass, left atrial area with/without indexing for body surface area, maximal septal thickness) and systolic function [ejection fraction, mitral annular plane systolic excursion (MAPSE), Tricuspid annular plane systolic excursion (TAPSE)] were assessed. A region of interest (ROI) was drawn in the basal septum in a four-chamber view in all patients and in the left atrium for blood T1 measurement as papillary muscle hypertrophy made drawing an ROI in the LV cavity challenging (see Figure 1); ROIs were mid-myocardial (at least two pixels away from the apparent blood:myocardial boundary) and were drawn without reference to the LGE images (see Figure 1).13 We quantified interstitial expansion with the ECV as described previously: ECV